Skip to content
Trial Eligibility
Menu

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

NCT05753059

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Heart Failure

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Sponsor
Yale University
Last updated on ClinicalTrials.gov
September 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Connecticut · 1

  • Yale University · New Haven, CT

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.